Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate

Abivertinib, one of Sorrento Therapeutics' (NASDAQ: SRNE) COVID-19 drug candidates, will be entering phase 2 testing in Brazil. This follows approval granted on Wednesday by the National Health Surveillance Agency (ANVISA), the country's healthcare regulator, which has cleared the U.S. company to advance the drug's development in the sprawling South American nation.

Abivertinib was originally designed to treat cancer; Sorrento believes it can limit the overactive immune systems seen in some COVID-19 patients.

In July, the drug was cleared for phase 2 testing in the U.S., but the Brazil study will have several differences. Among other distinctions, it will involve patients with mild, moderate, or severe forms of the illness; participants in the American trial are limited to severe COVID-19 cases. In Brazil, any hospitalized patient will be eligible; patients in the U.S. study must be in the intensive care unit and nonventilated.

A medical professional using a microscope.

Image source: Getty Images.

All told, Sorrento aims to recruit 400 participants in the Brazil trial. It says that its partnerships with local organizations and medical systems in the country should help it enroll that number quickly.

Testing Abivertinib on a population outside the so-called "first world" is intentional.

"By targeting some of the geographies currently most impacted by COVID-19, we are able to implement a synergistic program to answer questions about safety and efficacy of our drug candidates in helping patients, while potentially accelerating enrollment timelines, reducing overall cost and opening up collaboration opportunities with local companies," Sorrento quoted CEO Henry Ji as saying.

The company is one of numerous biotechs around the world engaged in the fight against COVID-19; Abivertinib is among a clutch of drugs and vaccines Sorrento is trying to develop for this purpose.

10 stocks we like better than Sorrento Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sorrento Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More